Tucatinib

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 281 publications

Efficacy evaluation of novel targeted drugs in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis based on multiple sets of clinical data.

Efficacy evaluation of novel targeted drugs in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis based on multiple sets of clinical data.

Journal: The Journal of international medical research

Published: July 14, 2026

Real-World Effectiveness and Safety of Tucatinib, Trastuzumab, and Capecitabine in HER2-Positive Advanced Breast Cancer: A Multicenter Portuguese Study.

Real-World Effectiveness and Safety of Tucatinib, Trastuzumab, and Capecitabine in HER2-Positive Advanced Breast Cancer: A Multicenter Portuguese Study.

Journal: European journal of breast health

Published: June 19, 2026

Clinical management of adverse events in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine.

Clinical management of adverse events in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine.

Journal: The oncologist

Published: June 11, 2026

HER2-Targeted Therapy for Metastatic Colorectal Cancer: Current Evidence, Patient Selection, and Practical Treatment Sequencing.

HER2-Targeted Therapy for Metastatic Colorectal Cancer: Current Evidence, Patient Selection, and Practical Treatment Sequencing.

Journal: Journal of gastrointestinal cancer

Published: May 17, 2026

Long-term cardiotoxicity outcomes of trastuzumab and cardiac safety of novel HER2-targeted therapies.

Long-term cardiotoxicity outcomes of trastuzumab and cardiac safety of novel HER2-targeted therapies.

Journal: Expert opinion on drug safety

Published: May 04, 2026

IGSF3 drives acquired temozolomide resistance in glioblastoma through ASNS-dependent asparagine biosynthesis.

IGSF3 drives acquired temozolomide resistance in glioblastoma through ASNS-dependent asparagine biosynthesis.

Journal: The Journal of biological chemistry

Published: March 31, 2026

Identification of small-molecule inhibitors targeting HER2 for breast cancer therapy using structure-based virtual screening, ADMET profiling, and molecular dynamics simulations.

Identification of small-molecule inhibitors targeting HER2 for breast cancer therapy using structure-based virtual screening, ADMET profiling, and molecular dynamics simulations.

Journal: Cellular and molecular biology (Noisy-le-Grand, France)

Published: March 16, 2026

Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence.

Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence.

Journal: Breast (Edinburgh, Scotland)

Published: March 12, 2026

Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer.

Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer.

Journal: Scientific reports

Published: March 10, 2026

Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.

Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: March 06, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; pembrolizumab for head and neck cancer, tucatinib for breast cancer, and trametinib for ovarian cancer.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; pembrolizumab for head and neck cancer, tucatinib for breast cancer, and trametinib for ovarian cancer.

Journal: International journal of clinical oncology

Published: February 28, 2026

Quantitation of Tucatinib, a Novel Tyrosine Kinase Inhibitor in Dried Blood Spot (DBS) With LC-ESI-MS/MS: Application to a Pharmacokinetic Study in Mice.

Quantitation of Tucatinib, a Novel Tyrosine Kinase Inhibitor in Dried Blood Spot (DBS) With LC-ESI-MS/MS: Application to a Pharmacokinetic Study in Mice.

Journal: Biomedical chromatography : BMC

Published: February 24, 2026

Showing 1-12 of 281

Last Updated: 09/26/2026